Curcumin and Brain Health — A Research Summary
Curcumin has compelling anti-inflammatory and anti-amyloid properties in laboratory research. Human bioavailability is poor, limiting translation to clinical benefit.
How it might work
Curcumin inhibits NF-kB (a master regulator of inflammatory gene expression), reduces amyloid-beta aggregation in vitro, promotes amyloid clearance, inhibits tau phosphorylation, and increases BDNF. The epidemiological observation that India has substantially lower Alzheimer's rates than Western countries has been attributed (speculatively) to turmeric consumption. The mechanism is compelling.
What the clinical trials show
The problem is bioavailability. Standard curcumin from turmeric is poorly absorbed from the gut — most passes through unabsorbed. Achievable blood levels are far below the concentrations needed for the effects seen in cell culture. A landmark 2018 UCLA RCT (Small et al., American Journal of Geriatric Psychiatry) used a highly bioavailable form (Theracurmin, 90mg twice daily) and found significant improvements in memory and attention vs. placebo over 18 months, along with reduced amyloid and tau accumulation on PET imaging — a genuinely important finding.
However, this single trial has not been replicated at scale. Most RCTs using standard curcumin find no significant cognitive effects, consistent with the bioavailability problem.
Strength of evidence
Weak for standard curcumin; a single promising trial for bioavailable forms. The UCLA PET imaging findings are intriguing but need replication. Until larger trials with highly bioavailable formulations confirm the finding, the clinical evidence remains insufficient to make strong recommendations.
Dosing used in research
The UCLA positive trial used Theracurmin at 90mg twice daily (180mg total). Equivalent highly bioavailable alternatives include Meriva (phytosome form), BCM-95, and Longvida. Standard curcumin supplements, even at high doses, likely do not achieve relevant brain concentrations.
Safety and considerations
Excellent safety profile at doses used in research. Mild GI effects possible. Curcumin inhibits certain CYP enzymes and can interact with drugs metabolized by those pathways — check drug interactions. High-dose curcumin may have mild anticoagulant effects. Avoid high doses in pregnancy.
Our take
The UCLA finding is compelling but isolated. If you want to trial curcumin for cognitive health, use a highly bioavailable form (Theracurmin, Meriva, Longvida) at research-relevant doses — standard curcumin capsules are unlikely to have cognitive effects regardless of dose. Replicated evidence from larger trials is needed before strong recommendations can be made.
Frequently asked questions
Does taking turmeric in food provide cognitive benefits?
Probably not at typical culinary amounts. The bioavailability of curcumin from turmeric is poor even with piperine (black pepper). The amounts achievable from food are far below the concentrations needed for the effects seen in laboratory research and in the UCLA trial using specialized formulations.
Is there any evidence that curcumin reduces amyloid in humans?
One study — the UCLA 2018 RCT using Theracurmin — found reduced amyloid and tau signals on PET imaging after 18 months. This is a single, small, unvalidated finding. It is intriguing but requires replication in larger trials before it changes clinical recommendations.
Which form of curcumin has the best absorption?
Theracurmin, Meriva (phytosome), BCM-95 (complexed with essential oils), and Longvida (lipid particle formulation) all significantly outperform standard curcumin. Piperine (black pepper extract) improves standard curcumin absorption 20-fold but still produces lower levels than specialized formulations.
Related resources
Start tracking your cognitive baseline
Four minutes a day. Five short tests. One trend line that builds over weeks and months so you can see where you stand — and separate a bad day from a real change.
Free to start. No account required. Not a diagnostic tool.